News by topic

Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Generic medicines news

Show

From To
PrEP
Most PrEP users in Berlin obtained it from informal channels

Over half of men who have sex with men (MSM) living in Berlin who were using HIV pre-exposure prophylaxis (PrEP) accessed it through informal sources, without consistent

Published
02 October 2018
By
Krishen Samuel
Pharmaceutical industry
CJEU Ruling on Truvada recalls ‘evergreening’ goes against public health interests

On 25th July 2018, the Court of Justice of the European Union (CJEU) rendered its preliminary ruling on the interpretation of Article 3(a) of Regulation (EC) No 469/2009 concerning the supplementary protection certificate (SPC) for medicinal products.

Published
10 September 2018
From
Medicines Law & Policy
Pharmaceutical industry
HIV drug may be more affordable after European court ruling

THE EUROPEAN COURT of Justice has delivered a ruling that could lead to wider access to affordable PrEP and significant savings on HIV treatment for the HSE. Pharma giant Gilead was today unsuccessful in a case relating to its HIV drug Truvada.

Published
26 July 2018
From
The Journal
PrEP policies and guidelines
UK HIV drugs bill may reduce following court ruling - implications for PrEP

A ruling today from the European Court of Justice (ECJ) suggests that Gilead’s patent for Truvada (the drug used to treat many people living with HIV, and the drug used for PrEP) may be under threat.

Published
25 July 2018
From
National AIDS Trust
Generic medicines
EU makes it easier for companies to produce generic medicines for export

The European Commission on Monday proposed to change intellectual property rules to let pharmaceutical companies produce generic drugs for export to countries and regions where they are not under extended patent protection.

Published
29 May 2018
From
Reuters
Pharmaceutical industry
Will the European Court of Justice put a stop to the evergreening of Truvada patents?

Since July 2017, Truvada has been available in generic forms in some European countries (eg. the Netherlands, France) but not in others (eg. UK, Switzerland). This is because the key patent covering tenofovir disoproxil expired in July 2017 in most countries, but not in all. In Europe, some countries have extended the duration of the tenofovir patent beyond the 20-year patent term by granting a supplementary protection certificate (SPC).

Published
09 May 2018
From
Medicines Law & Policy
Finance and funding
NHS England saved £10 million by switching to generic anti-HIV drugs in 2016

A programme to encourage clinicians to switch people to generic antiretroviral drugs saved the NHS almost £10 million in the financial year 2016-2017, Dr Laura

Published
30 April 2018
By
Roger Pebody
Pharmaceutical industry
A Cheaper Version of Truvada Is Hitting the US Market: Here's Why It Might Not Lower Costs

Coming to U.S. pharmacies this month is Cimduo, from drugmaker Mylan. It's essentially a copycat of Truvada (TDF/FTC), but there's good reason to believe that, despite its lower price, Mylan just won't catch on. And the reasons point to the bigger issue of why it's so hard in general to bring down to earth the price of HIV drugs.

Published
04 April 2018
From
The Body
Pharmaceutical industry
Janssen HIV Drug U.K. Patent Extension Case to Go to EU Top Court

Sandoz Ltd.’s lawsuit to clear the way for its generic version of the Prezista HIV drug will now go to the Court of Justice of the European Union. The trial court sided with Janssen, saying that the SPC covered Prezista.

Published
07 February 2018
From
Bloomberg
Generic medicines
Generic drugs for HIV treatment may save money, but barriers to prescription make savings elusive

The potential savings from prescribing generic antiretrovirals predicted by economic models may be overstated and numerous barriers need to be overcome to bring down the

Published
07 February 2018
By
Keith Alcorn
← Prev12345...6Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.